FY2025 EPS Estimates for Sanuwave Health Raised by Analyst

Key Points

• Roth Capital has raised its FY2025 earnings per share estimate for Sanuwave Health from $0.26 to $0.42, maintaining a "Buy" rating and a $55.00 price target for the stock.
• Sanuwave Health reported Q2 earnings of $0.01 per share, exceeding analysts' expectations of a loss, alongside revenues of $10.16 million.
• Institutional investors hold approximately 42.53% of Sanuwave Health's stock, with several major investments made in the last quarter.

Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) - Analysts at Roth Capital upped their FY2025 earnings per share estimates for shares of Sanuwave Health in a note issued to investors on Sunday, September 28th. Roth Capital analyst K. Bauser now anticipates that the company will post earnings per share of $0.42 for the year, up from their prior estimate of $0.26. Roth Capital currently has a "Buy" rating and a $55.00 price objective on the stock. Roth Capital also issued estimates for Sanuwave Health's Q4 2025 earnings at $0.37 EPS, Q1 2026 earnings at $0.17 EPS, Q2 2026 earnings at $0.30 EPS, Q3 2026 earnings at $0.44 EPS, Q4 2026 earnings at $0.59 EPS, FY2026 earnings at $1.50 EPS and FY2027 earnings at $2.34 EPS.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.10. The company had revenue of $10.16 million for the quarter, compared to analysts' expectations of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

SNWV has been the topic of several other reports. Northland Securities initiated coverage on shares of Sanuwave Health in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $55.00 target price on the stock. Northland Capmk raised shares of Sanuwave Health to a "strong-buy" rating in a research note on Wednesday, September 3rd. Finally, Wall Street Zen lowered shares of Sanuwave Health from a "buy" rating to a "hold" rating in a research note on Saturday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $55.00.

Sanuwave Health Stock Performance

SNWV stock opened at $37.48 on Wednesday. The stock's 50-day moving average price is $37.73. Sanuwave Health has a 52-week low of $5.63 and a 52-week high of $46.58. The stock has a market cap of $321.20 million, a price-to-earnings ratio of -4.54 and a beta of 1.39.

Institutional Investors Weigh In On Sanuwave Health

Several large investors have recently bought and sold shares of the company. Legal & General Group Plc purchased a new stake in Sanuwave Health during the 2nd quarter worth approximately $26,000. Strategic Investment Solutions Inc. IL purchased a new stake in Sanuwave Health during the 1st quarter worth approximately $47,000. BNP Paribas Financial Markets purchased a new stake in Sanuwave Health during the 2nd quarter worth approximately $46,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Sanuwave Health during the 2nd quarter worth approximately $52,000. Finally, New York State Common Retirement Fund acquired a new stake in Sanuwave Health in the 2nd quarter valued at about $102,000. 42.53% of the stock is currently owned by hedge funds and other institutional investors.

About Sanuwave Health

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.